- Report
- December 2025
Global
From €600EUR$729USD£542GBP
- Report
- December 2025
Global
From €450EUR$547USD£406GBP
- Report
- December 2025
Global
From €450EUR$547USD£406GBP
- Report
- December 2025
Global
From €450EUR$547USD£406GBP
- Report
- December 2025
Global
From €300EUR$365USD£271GBP
- Report
- December 2025
Global
From €300EUR$365USD£271GBP
- Report
- December 2025
Global
From €200EUR$243USD£181GBP
- Report
- August 2023
- 267 Pages
Global
From €2150EUR$2,612USD£1,941GBP
- Report
- February 2023
- 96 Pages
Global
From €1800EUR$2,187USD£1,625GBP
- Report
- June 2022
- 115 Pages
Global
From €1050EUR$1,276USD£948GBP
- Report
- May 2022
- 50 Pages
Global
From €500EUR$608USD£451GBP
- Report
- May 2022
- 32 Pages
Global
From €400EUR$486USD£361GBP
- Report
- October 2021
- 433 Pages
Global
From €2250EUR$2,734USD£2,031GBP
- Report
- July 2024
- 266 Pages
Global
From €4364EUR$4,950USD£3,806GBP
- Report
- July 2024
- 335 Pages
Global
From €4364EUR$4,950USD£3,806GBP
- Report
- April 2024
- 270 Pages
Global
From €4408EUR$5,000USD£3,844GBP
- Report
- February 2022
- 272 Pages
Global
From €5290EUR$6,000USD£4,613GBP
- Report
- January 2024
- 140 Pages
Global
From €2909EUR$3,300USD£2,537GBP
- Report
- October 2022
- 510 Pages
China
From €2116EUR$2,400USD£1,845GBP
- Report
- October 2019
Global
From €2469EUR$2,800USD£2,153GBP

T Cell Therapies are a type of biotechnology that involves the use of a patient's own T cells to treat diseases. T cells are a type of white blood cell that play a key role in the body's immune system. T Cell Therapies involve the extraction of T cells from a patient, engineering them to recognize and attack specific targets, and then reintroducing them into the patient's body. This type of therapy has been used to treat a variety of cancers, including leukemia, lymphoma, and multiple myeloma. It has also been used to treat autoimmune diseases, such as rheumatoid arthritis and Crohn's disease.
T Cell Therapies are a rapidly growing field of biotechnology, with many companies investing in research and development. Companies such as Kite Pharma, Juno Therapeutics, and Novartis are leading the way in developing and commercializing T Cell Therapies. Other companies, such as Gilead Sciences, Celgene, and Regeneron, are also investing in the field. Show Less Read more